Nurix Therapeutics (NRIX) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 131.2% versus a loss of 24.3%. Over five years, PBH leads with a -18.6% price change compared with -21.2% for NRIX. Nurix Therapeutics is the larger company by market cap ($2.30 billion vs $2.25 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | PBH |
|---|---|---|
| Share price | $22.12 | $47.43 |
| Market cap | $2.30B | $2.25B |
| 1-day change | -2.68% | -0.29% |
| YTD return | +19.82% | -22.89% |
| 1-year return | +131.23% | -24.34% |
| 5-year return | -21.16% | -18.57% |
| P/E ratio (TTM) | — | 13.29 |
| Forward P/E | — | 9.33 |
| EPS (TTM) | $-3.46 | $3.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.23 | $71.07 |
| 52-week low | $9.00 | $42.62 |
| Distance from 52-week high | -21.64% | -33.26% |
| Analyst consensus | none | buy |
| Avg. price target upside | +53.39% | +42.95% |
| Average volume | 1.27M | 545.45K |
| Shares outstanding | 103.78M | 47.37M |
| Employees | 317 | 890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed PBH by 155.6 percentage points over the past year.
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
NRIX vs PBH FAQ
Which is bigger, Nurix Therapeutics or Prestige Consumer Healthcare?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $2.30B compared with $2.25B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, NRIX or PBH?
NRIX returned +131.23% over the past 12 months, compared with -24.34% for PBH (price return, excluding dividends). Past performance does not predict future results.
Are Nurix Therapeutics and Prestige Consumer Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.